Clinical Trials

Clinical trials are studies that evaluate the effectiveness of new drugs or treatment strategies. The development of more effective cancer treatments requires that new and innovative therapies be evaluated with cancer patients. Each clinical trial is designed to find new or better ways to treat cancer patients.

It is extremely important to decide whether or not to participate in a clinical trial before receiving any treatment from a physician.

The following clinical trials are now under way at McLeod Cancer & Blood Center:

Iron Deficiency Anemia

LUITPOLD — 1VIT08019
A Multi-Center, Randomized, Controlled Study to Investigate the Safety and Tolerability of Intravenous Ferric Carboxymaltose (FCM) vs. Standard Medical Care in Treating Iron Deficiency Anemia

LUITPOLD — 1VIT09021
A Multi-Center, Randomized, Controlled Study to Investigate the Safety and Tolerability of a Single Dose of Intravenous Ferric Carboxymaltose (FCM) vs. Standard Medical Care in Treating Iron Deficiency Anemia in Subjects Who Are Not Dialysis Dependent

Breast Cancer

BETH
A Multi-Center Phase III Randomized Trial of Adjuvant Therapy for Patients with HER2-Positive Node-Positive or High Risk Node-Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab

CLEOPATRA
A Phase III Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated Her2 Positive Metastatic Breast Cancer

VIRGO — AVF4349n
An Observational Study of Treament Patterns and Safety Outcomes for Metastatic or Locally Recurrent Breast Cancer

Lung Cancer

AVF3991n
An Observational Study of Avastin (Bevacizumab) in Combination with Chemotherapy for Treatment of Metastatic or Locally Advanced and Unresectable Colorectal Cancer, Locally Advanced or Metastatic Non-Small Cell Lung (Excluding Predominant Squamous Cell Histology), or Locally Recurrent or Metastatic Breast Cancer

PSHCI08-009
A Multicenter, Open-Label, Randomized, Phase II Trial of Docetaxel, Carboplatin and Bevacizumab as First-Line Treatment, Followed by Bevacizumab plus Pemetrexed versus Pemetrexed Alone as Second-Line Treatment of Stage IIIB or IV Non-Small Cell Lung Cancer (NSCLC)

Lymphoma

PREMIER
A Randomized,OpenLabel, Phase II Trial comparing Rituximab Plus Sargramostim to Rituximab Monotherapy for the Treatment of Relapsed Follicular B-Cell Lymphoma

C05011
Phase II Study of Velcade (Bortezomib) in Combination with Bendamustine and Rituximab to Subjects With Relapsed or Refractory Follicular Lymphoma

RATE — U4391g
A Phase III Multicenter, Open Label Study of Rituximab Faster Infusion Time in Patients with Previously Untreated Diffuse Large B-Cell or Follicular Non-Hodgkin's Lymphoma